- If you are wondering whether Ascendis Pharma's share price still offers value after a strong run, the key is to look closely at what the current valuation actually reflects.
- The stock last closed at US$228.73, with returns of 6.1% over 7 days, a 2.0% decline over 30 days, 7.2% year to date, 51.0% over 1 year, 220.2% over 3 years and 73.7% over 5 years.
- Recent price moves have come alongside ongoing attention on Ascendis Pharma's pipeline progress and funding position, as investors reassess the balance between potential rewards and risks. News flow around regulatory milestones, capital needs or major partnerships can quickly influence sentiment and help explain why the share price has not moved in a straight line.
- On Simply Wall St's valuation checks, Ascendis Pharma scores 3 out of 6. The next sections will break down what different valuation methods suggest, and then conclude with a broader way to think about what the current price might be indicating.
Approach 1: Ascendis Pharma Discounted Cash Flow (DCF) Analysis
A Discounted Cash Flow, or DCF, model takes estimates of the cash Ascendis Pharma could generate in the future and discounts those cash flows back to today to arrive at an implied value per share.
Ascendis Pharma’s latest twelve month free cash flow is about €47.3 million. Based on analyst inputs and further projections, Simply Wall St models free cash flow rising to €1.36 billion by 2030, with a 2 Stage Free Cash Flow to Equity framework used to extend estimates out to 2035. Each future cash flow in this path is discounted back to its present value and then aggregated.
On this basis, the model arrives at an estimated intrinsic value of US$816.95 per share, compared with the recent share price of US$228.73. That indicates the stock is trading at a 72.0% discount to the DCF estimate, suggesting a wide gap between the current market price and this cash flow based valuation.
Result: UNDERVALUED
Our Discounted Cash Flow (DCF) analysis suggests Ascendis Pharma is undervalued by 72.0%. Track this in your watchlist or portfolio, or discover 58 more high quality undervalued stocks.
Approach 2: Ascendis Pharma Price vs Sales
For companies where profits are not yet the main focus, the P/S ratio is often more useful than P/E or P/B because it compares what you pay for each dollar of revenue rather than each dollar of earnings or book value.
What counts as a “normal” or “fair” P/S multiple typically reflects how quickly investors expect revenue to grow and how much risk they see in the business model, with higher expected growth or lower perceived risk often supporting a higher multiple.
Ascendis Pharma currently trades on a P/S ratio of 16.87x. This is above the Biotechs industry average of 10.64x and also above the peer group average of 13.01x, so on simple comparisons the valuation looks relatively full.
Simply Wall St’s Fair Ratio for Ascendis Pharma is 14.78x. This is a proprietary estimate of what the P/S multiple could be given factors such as earnings growth, industry, profit margins, market cap and key risks. This tends to be more tailored than a straight peer or industry comparison because it adjusts for company specific characteristics.
Comparing the Fair Ratio of 14.78x with the current 16.87x P/S suggests the shares are trading at a premium to this customised benchmark.
Result: OVERVALUED
P/S ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 20 top founder-led companies.
Upgrade Your Decision Making: Choose your Ascendis Pharma Narrative
Earlier it was mentioned that there is an even better way to understand valuation, so Narratives are introduced as a simple way for you to write the story behind the numbers. They do this by linking your view of Ascendis Pharma’s products, competition and risks to explicit estimates for future revenue, earnings and margins. These then flow through to a Fair Value that can be compared with the current share price on Simply Wall St’s Community page. Narratives are available to millions of investors and refresh automatically as new news or earnings arrive. They can also differ widely. For example, one Ascendis Pharma Narrative may lean toward a higher Fair Value of about US$338 based on assumptions closer to the more optimistic analyst cohort. Another might sit nearer US$193 based on more cautious assumptions. This can help you see how different stories about Yorvipath, Yuviwel and the TransCon platform translate into different Fair Values and clearer decisions about whether the current price looks high, low or roughly in line with your own expectations.
Do you think there's more to the story for Ascendis Pharma? Head over to our Community to see what others are saying!
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com